Juniper Pharma (JNP) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results
May 6, 2015 7:01 AM EDTBOSTON, May 6, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), today announced financial results for the three-month period ended March 31, 2015. First quarter financial highlights include:
Total revenues were $8.3 million, an increase of 19% as compared to $7.0 million in the first quarter of 2014; Product revenues increased 41% year-over-year, enabled by the return of normalized CRINONE® (progesterone gel) shipments to Merck Serono in the fourth quarter of 2014; Service revenues grew 9% year-over-year and 42% from the fourth quarter of 2014, on a local currency basis; Operating profit... More